Jerusalem: Antibody can develop on its own to fight the novel coronavirus in most people severely affected by Covid-19. A study has said this by supporting the use of Antibodies Therapy to avoid and treat the disease.
Researchers said that antibodies specifically attacking the receptor-binding domain (RBD) of the SARS-Cove-2 spike protein are considered essential for controlling Covid-19. The virus uses RDB to enter human cells.
The study, conducted by a team comprising researchers from Tel Aviv University in Israel, states that RDB-centered antibodies were found in people recovering from Covid-19. He said that some people who have recovered from the infection have seen tremendous and long-lasting immunity, while others have relatively weak antibodies.
The study, published in the journal ‘PLOS Pathogens’, compared B-cell responses to eight and a half of severely symptomatic Covid-19 and 10-and-a-half months after being infected with the virus by 10 individuals with mild symptoms. Molecular and bioinformatics techniques were used for this.
The B-cell immune system is responsible for the development of antigen-centered immunoglobulin (Ig) against invasive pathogens. The research found that high concentrations of RBD-specific antibodies were found in very ill patients and increased B-cell. Of the 22 antibodies produced in two of these patients, six had the ability to fight SARS-Cove-2.
The researchers said, “Biopharmatics analysis showed that most severe patients with Covid-19 developed antibodies against SARS-Cove-2 on their own.”
